0000000000465905

AUTHOR

Thomas Frodl

showing 4 related works from this author

Real-world evidence from a European cohort study of patients with treatment resistant depression : Baseline patient characteristics

2021

Journal of affective disorders 283, 115-122 (2021). doi:10.1016/j.jad.2020.11.124

AdultMaleDisease burden; Health-related quality of life; Major depressive disorder; Observational study; Patient-reported outcomes; Socio-economic status; Adult; Cohort Studies; Europe; Female; Humans; Male; Middle Aged; Quality of Life; Depressive Disorder Major; Depressive Disorder Treatment-Resistantmedicine.medical_specialtyHealth-related quality of lifeSocio-economic statusMajor depressive disorderCohort Studies03 medical and health sciencesDepressive Disorder Treatment-Resistant0302 clinical medicineQuality of lifeObservational studyInternal medicinemedicineHumansMedical historyDepression (differential diagnoses)Disease burdenDepressive DisorderDepressive Disorder MajorPatient-reported outcomesDisease burden Health-related quality of life Major depressive disorder Observational study Patient-reported outcomes Socio-economic statusbusiness.industryTreatment-ResistantMajorDisease burdenMiddle Agedmedicine.disease030227 psychiatry3. Good healthEuropePsychiatry and Mental healthClinical PsychologyPresenteeismQuality of LifeMajor depressive disorderFemalebusinessTreatment-resistant depression030217 neurology & neurosurgeryCohort study
researchProduct

Real-world evidence from a European cohort study of patients with treatment resistant depression:Healthcare resource utilization

2022

Journal of affective disorders 298, Part A 442-450 (2022). doi:10.1016/j.jad.2021.11.004 special issue: "Special Issue on Corona Virus / Edited by Allan Young, Ron Acierno, Xiang Yang Zhang"

Healthcare resource utilization Major depressive disorder Observational study Real-world evidence Treatment resistant depressionmedicine.medical_specialtyMajor depressive disorderTreatment resistant depressionCohort StudiesIndirect costsDepressive Disorder Treatment-ResistantHealthcare resource utilization; Major depressive disorder; Observational study; Real-world evidence; Treatment resistant depressionObservational studyHealth careHealthcare resource utilizationmedicineHumansMajor depressive episodeDepression (differential diagnoses)Retrospective StudiesReal-world evidenceDepressive DisorderDepressive Disorder Majorbusiness.industryTreatment-ResistantMajorHealth Care Costsmedicine.diseasePsychiatry and Mental healthClinical PsychologyEmergency medicineMajor depressive disorderObservational studymedicine.symptombusinessHealthcare resource utilization; Major depressive disorder; Observational study; Real-world evidence; Treatment resistant depression; Cohort Studies; Delivery of Health Care; Health Care Costs; Humans; Retrospective Studies; Depressive Disorder Major; Depressive Disorder Treatment-ResistantTreatment-resistant depressionDelivery of Health CareCohort study
researchProduct

Real-world evidence from a European cohort study of patients with treatment resistant depression: Treatment patterns and clinical outcomes.

2021

Abstract Background Treatment resistant depression (TRD) characterizes a subgroup of 10–30% of patients with major depressive disorder, and is associated with considerable morbidity and mortality. A consensus treatment for TRD does not exist, which often leads to wide variations in treatment strategies. Real-world studies on treatment patterns and outcomes in TRD patients in Europe are lacking and could help elucidate current treatment strategies and their efficacy. Methods This non-interventional cohort study of patients with TRD (defined as treatment failure on ≥2 oral antidepressants given at adequate dose and duration) with moderate to severe depression collected real-world data on trea…

Moderate to severemedicine.medical_specialtyMEDLINEAntidepressive Agents; Cohort Studies; Europe; Humans; Depressive Disorder Major; Depressive Disorder Treatment-ResistantReal world evidenceTreatment failureCohort Studies03 medical and health sciencesDepressive Disorder Treatment-Resistant0302 clinical medicineInternal medicinemedicineHumansPsiquiatriaDepression (differential diagnoses)Depressive DisorderDepressive Disorder Majorbusiness.industryTreatment-ResistantMajormedicine.diseaseAntidepressive Agents030227 psychiatryEuropePsychiatry and Mental healthClinical PsychologyMajor depressive disorderbusinessTreatment-resistant depression030217 neurology & neurosurgeryCohort studyJournal of affective disorders
researchProduct

Reduced oxytocin receptor gene expression and binding sites in different brain regions in schizophrenia: A post-mortem study

2016

Schizophrenia is a severe neuropsychiatric disorder with impairments in social cognition. Several brain regions have been implicated in social cognition, including the nucleus caudatus, prefrontal and temporal cortex, and cerebellum. Oxytocin is a critical modulator of social cognition and the formation and maintenance of social relationships and was shown to improve symptoms and social cognition in schizophrenia patients. However, it is unknown whether the oxytocin receptor is altered in the brain. Therefore, we used qRT-PCR and Ornithine Vasotocin Analog ([125I]OVTA)-based receptor autoradiography to investigate oxytocin receptor expression at both the mRNA and protein level in the left p…

AdultMaleGene ExpressionVasotocinReal-Time Polymerase Chain ReactionLeft nucleusRats Sprague-Dawley03 medical and health scienceschemistry.chemical_compound0302 clinical medicinemedicineHaloperidolAnimalsHumansRNA MessengerClozapineBiological PsychiatryClozapineAgedAged 80 and overTemporal cortexBinding SitesBrainMiddle Agedmedicine.diseaseOxytocin receptor030227 psychiatryPsychiatry and Mental healthchemistryOxytocinReceptors OxytocinSchizophreniaSchizophreniaAutoradiographyHaloperidolFemalePsychologyNeurosciencehormones hormone substitutes and hormone antagonists030217 neurology & neurosurgeryAntipsychotic Agentsmedicine.drugSchizophrenia Research
researchProduct